ADVA
21.1.2020 09:02:12 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has successfully demonstrated Europe’s first 5G rail deployment in an operational environment. Using a combined optical and microwave transport solution, the demo succeeded in delivering multi-Gbit/s connectivity to fast-moving trains. Until now, supporting the handovers required for consistent broadband connectivity on trains traveling at speed was a major challenge. Built on ADVA’s G.metro passive optical technology and FSP 150 edge aggregation solution , the joint trial featured an integrated architecture for all train communication applications. Millimeter wave (mmWave) access points (APs) were used to maintain track-to-train connectivity as well as programmable mobility functions for seamless onboard services. Part of the EU’s Horizon 2020 5G-PICTURE project, the demo was conducted by ADVA, Blu Wireless Technology, CNIT, COMSA Industrial and the local railway operator and infrastructure manager, Ferrocarrils de la Generalitat de Catalunya (FGC).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200121005201/en/
“With this demo, we’ve presented the blueprints for the future of rail telecommunication networks. We’ve shown how a combined optical and microwave 5G architecture can carry both critical and non-critical communications, dramatically simplifying deployments and delivering significant cost reduction,” said Jim Zou, senior engineer, advanced technology, ADVA. “Unlike traditional railway telecommunication networks that rely on separate infrastructures, what we’ve proposed with this demo is a unified, automated network able to support every application and prevent service interruptions. It delivers high-bandwidth internet access to passengers on the move, while also providing train operators with driver-to-control connectivity, access to surveillance cameras and mission-critical onboard applications. Now a single 5G network can provide all telco services for train companies, freight operators and passengers.”
Deployed across three stations of the FGC network in Barcelona, the 5G-PICTURE railway testbed interconnected a variety of end-user devices and compute resources using the most advanced optical and wireless network technologies. For the first time in Europe in a live operational scenario, the demo proved that a single integrated infrastructure can deliver safe, secure and reliable connectivity for all three categories of train line services: critical, performance and business. Along the track, it leveraged mmWave links that intelligently steered beams to the train’s rooftop antennae for optimal backhaul and access connectivity. These were connected to passive WDM add/drop nodes built with ADVA’s low-latency G.metro system and each mmWave AP was capable of dedicated 10Gbit/s connectivity. All the traffic from the trackside was further aggregated to the railway operator’s core network based on ADVA’s 100Gbit/s Ethernet aggregation technology.
“At FGC, we understand the value of leveraging emerging technology to achieve maximum efficiency and provide our passengers with the best available services. That’s why we’re so excited by the possibilities that this demo presents. It showed how we can harness an intelligent, open and scalable 5G network for everything from surveillance to passenger communications to mission-critical operational data transport,” commented Carles Terés Casals, director, R&D, FGC. “Train passengers are heavy users of mobile data. Whether it’s video streaming, replying to emails and social media or planning the next stage of their journey, they expect always-on access to advanced services. Providing ultra-reliable high-speed mobility on a virtual infrastructure shared with all other applications offers a way to meet that demand while removing complexity and saving significant cost.”
“This project is about completely transforming on-train connectivity for the digitalization strategy of the railway sector. It’s about providing massive high-quality wireless capacity to trains to enable cloud-based applications that improve performance and security in the railway sector. It’s also about being able to support new business and passenger applications,” said Manuel Alfageme, head of smart systems innovation, COMSA Industrial. “At COMSA, we have a formidable record of leading the way with rail innovation. By jointly demonstrating the technical and commercial viability of this technology in a live operational environment, we’re showing train operators and railway infrastructure managers that open, scalable and agile 5G networks are now possible in the railway vertical. The time has come for a new generation of integrated railway infrastructure.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200121005201/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
